Education
About Us
Working with TipRanks
Follow Us
Processa Pharmaceuticals, Inc. (PCSA)
:PCSA
PCSA Stock Chart & Stats
$0.12
-$0.13(-13.68%)
At close: 4:00 PM EST
$0.12
-$0.13(-13.68%)
Day’s Range― - ―
52-Week Range$2.73 - $27.00
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.50M
Market Cap
$8.56M
Enterprise Value$221.81M
Total Cash (Recent Filing)$6.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding2,265,769
10 Day Avg. Volume4,405,168
30 Day Avg. Volume1,500,663
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)39.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.01
Enterprise Value/Market Cap25.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-17.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-10.5
Revenue Forecast (FY)$14.91M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPositive interim data from the NGC-Cap mid-stage trial should constitute a meaningful value inflection point.
Financial StabilityThe company ended 2Q25 with roughly $6.9M in cash and cash equivalents, which is expected to be sufficient to fund operations into early 2026.
Strategic InvestmentsProcessa recently announced that it secured a strategic investment and is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives.
Bears Say
Financial ConstraintsAdditional capital will be required to fully fund the ongoing Phase 2 trial, and there is a concern that challenging financing conditions can limit the ability to complete the study.
Market ComplianceProcessa has received a notice from the NASDAQ exchange indicating that it is not currently in compliance with the minimum bid price requirement due to the low current share price.
Patient Enrollment DelaysThe required patients for the interim analysis of the Phase 2 trial have not enrolled yet, and it remains unclear when they will enroll due to the cash balance.
Processa Pharmaceuticals News
PCSA FAQ
What was Processa Pharmaceuticals, Inc.’s price range in the past 12 months?
Processa Pharmaceuticals, Inc. lowest stock price was $2.73 and its highest was $27.00 in the past 12 months.
What is Processa Pharmaceuticals, Inc.’s market cap?
Processa Pharmaceuticals, Inc.’s market cap is $8.56M.
When is Processa Pharmaceuticals, Inc.’s upcoming earnings report date?
Processa Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 225 days.
How were Processa Pharmaceuticals, Inc.’s earnings last quarter?
Processa Pharmaceuticals, Inc. released its earnings results on Nov 05, 2025. The company reported -$1.75 earnings per share for the quarter, beating the consensus estimate of -$2 by $0.25.
Is Processa Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Processa Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Processa Pharmaceuticals, Inc. pay dividends?
Processa Pharmaceuticals, Inc. does not currently pay dividends.
What is Processa Pharmaceuticals, Inc.’s EPS estimate?
Processa Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Processa Pharmaceuticals, Inc. have?
Processa Pharmaceuticals, Inc. has 2,265,769 shares outstanding.
What happened to Processa Pharmaceuticals, Inc.’s price movement after its last earnings report?
Processa Pharmaceuticals, Inc. reported an EPS of -$1.75 in its last earnings report, beating expectations of -$2. Following the earnings report the stock price went down -1.734%.
Which hedge fund is a major shareholder of Processa Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PCSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals (PCSA) is a clinical-stage biopharmaceutical company focused on developing innovative drug products to address unmet medical needs. Operating primarily in the biopharmaceutical and healthcare sectors, the company is committed to advancing its pipeline of promising drug candidates through various stages of clinical development to ultimately improve patient outcomes.
PCSA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
1.22% Insiders
0.12% Mutual Funds
2.03% Other Institutional Investors
96.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---